Zentek Ltd. (NASDAQ:ZTEK) Short Interest Update

Zentek Ltd. (NASDAQ:ZTEK) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 148,000 shares, a decline of 25.1% from the February 13th total of 197,500 shares. Based on an average daily volume of 45,800 shares, the short-interest ratio is currently 3.2 days. Approximately 0.2% of the company’s stock are short sold.

Zentek Stock Performance

Shares of ZTEK opened at $0.92 on Friday. The company’s 50 day moving average price is $1.05 and its 200 day moving average price is $0.95. Zentek has a 52 week low of $0.50 and a 52 week high of $1.34. The company has a market capitalization of $95.76 million, a PE ratio of -13.11 and a beta of 1.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.83.

Zentek (NASDAQ:ZTEK) last posted its earnings results on Wednesday, February 12th. The company reported ($0.01) EPS for the quarter. Zentek had a negative return on equity of 58.13% and a negative net margin of 16,555.32%.

Institutional Trading of Zentek

Several large investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC bought a new stake in Zentek in the fourth quarter worth approximately $31,000. Scotia Capital Inc. grew its position in Zentek by 5.7% in the fourth quarter. Scotia Capital Inc. now owns 958,771 shares of the company’s stock worth $867,000 after acquiring an additional 51,744 shares in the last quarter. Finally, Anson Funds Management LP bought a new stake in Zentek in the fourth quarter worth approximately $145,000. 0.77% of the stock is owned by institutional investors.

About Zentek

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.